查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016901

旅行疫苗市場：按疫苗類型、劑型、年齡層和最終用戶分類的全球市場預測 – 2026-2032 年

Travel Vaccines Market by Vaccine Type, Form, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，旅行疫苗市場價值將達到 141.3 億美元，到 2026 年將成長至 153.6 億美元，到 2032 年將達到 259.3 億美元，複合年成長率為 9.06%。

主要市場統計數據
基準年 2025 141.3億美元
預計年份：2026年 153.6億美元
預測年份 2032 259.3億美元
複合年成長率 (%) 9.06%

本文說明了在旅行模式不斷變化和旅行者期望不斷提高的情況下，觀點旅行疫苗接種仍然至關重要。

隨著跨境旅行的恢復和日益多樣化，與旅行相關的免疫接種仍然是一項至關重要的公共衛生措施。行前接種疫苗不僅能保護旅客個人，還能透過控制與旅遊、商務旅行、移民和人道工作相關的疫苗可預防疾病的傳播，進而保護整個目的地社區。旅客在準備出行時會參考不斷變化的信息，包括臨床指南、目的地特定的入境要求和電子健康證明，這些因素影響著對主要疫苗（例如肝炎、流感和黃熱病疫苗）的需求模式。

科學創新、數位技術的應用以及監管的複雜性如何交織，從而重塑全球旅行疫苗接種模式和相關人員的策略？

在疫苗科學的進步、數位醫療的整合以及地緣政治格局對供應鏈的影響下，旅行疫苗領域正經歷著一場變革。包括新型平台和改進的低溫運輸解決方案在內的技術進步，使得疫苗配方更加持久耐用且適應性更強，從而影響著疫苗接種計劃、儲存要求和分發方式。同時，用於管理疫苗接種記錄、行前風險評估和預約安排的數位醫療工具，正在重塑患者體驗，並將網路基地台拓展到傳統臨床環境之外。

檢驗進口關稅趨勢變化對整個旅行免疫網路的採購、低溫運輸物流和服務交付的連鎖反應。

貿易和海關政策的變化會對疫苗及相關物資的物流和供應產生重大影響，而這些物資正是旅遊免疫計畫的基礎。疫苗成分、包裝材料或低溫運輸設備的進口關稅或海關稅的增加，將促使供應鏈上的相關人員調整其採購和庫存策略，以應對成本壓力並維持利潤率。製造商和經銷商可能會修改與供應商的契約，加快本地化進程，或優先儲備關鍵投入品以減少供應中斷。

實用的細分見解，闡明了疫苗類型、給藥方法、年齡層和最終用戶管道應如何在差異化的臨床和商業策略的製定中體現出來。

對市場區隔的深入理解對於最佳化整個旅行疫苗接種生態系統中的臨床指導、分發方式和商業策略至關重要。疫苗類型和成分是關鍵因素，因為不同的病原體和接種方案——例如甲型和乙型肝炎、流感、腦膜炎球菌病菌感染、狂犬病、傷寒和黃熱病——會導致不同的臨床緊急程度、旅行前接種時間和儲存要求。因此，供應優先順序和臨床醫生工作流程必須反映這些臨床差異。劑型會影響供應物流和病人偏好。雖然注射疫苗因其有效性和成熟的給藥方案而在臨床實踐中佔據主導地位，但口服疫苗可以為某些旅行者群體提供替代方案，並有助於在資源匱乏或偏遠地區進行分發。

美洲、歐洲、中東和非洲以及亞太市場旅行疫苗接種的區域趨勢和實際影響

地理環境影響疾病流行情況、法律規範和服務提供模式，因此需要針對不同地區採取相應的旅遊疫苗接種策略。在美洲，公共衛生系統和私人機構正在攜手合作，共同應對南美部分地區黃熱病等地方性疾病的風險，並支持與旅行模式重疊的大規模季節性流感疫苗宣傳活動。該地區還擁有完善的分發網路，並且數位健康證明的使用率不斷提高，這使得在不同次區域間流動的旅客能夠更便捷地完成行前篩檢和疫苗接種後的記錄工作。

主要製造商、經銷商和服務供應商如何重組其產品組合、夥伴關係和業務永續營運，以確保旅行者疫苗的供應？

產業相關人員正透過調整產品組合、拓展經銷夥伴以及投資生產和物流能力，來滿足臨床需求並掌握商業性機會。領先的疫苗生產商和產品開發商正在擴展開發平臺，以應對旅遊相關病原體的多樣性，並提高製劑穩定性和給藥便利性。同時，經銷商和服務供應商正在加強與專業旅行診所和藥房網路的合作，以簡化預約管理、低溫運輸管理和記錄保存流程。

產業領導者應採取切實可行的、高優先順序的策略步驟，以增強供應鏈韌性、數位化管道和有針對性的相關人員參與。

旅行疫苗生態系統的領導者應優先考慮一系列切實可行的舉措，以提升臨床服務的提供及其商業性可行性。首先，投資供應鏈冗餘和低溫運輸最佳化，以降低貿易政策波動和物流中斷帶來的風險。這包括尋找替代供應商、建立區域填充和包裝能力，以及建立透明的庫存管理系統。其次，加快在旅客行程中整合數位化流程，透過實施可互通的疫苗接種記錄、行前遠距遠端醫療健康檢查以及自動化的預約和疫苗接種提醒，提高疫苗接種率並最大限度地減少錯失接種機會。

為了深入了解旅行疫苗接種的實際情況，我們採用了嚴謹的混合方法研究途徑，結合了初步訪談、政策審查和供應鏈分析。

支持這些發現的研究採用了混合方法，旨在涵蓋旅行疫苗接種的臨床、營運和政策層面。研究人員對臨床醫生、旅遊醫學專家、供應鏈管理人員和監管專家進行了初步的定性訪談，以直接了解服務提供的挑戰和應對策略。此外，研究人員還整合了二手資訊、同儕審查文獻、公共衛生機構指南、貿易政策文件和物流報告，以檢驗影響跨境疫苗流通的臨床路徑、儲存要求和法規環境。

總結整合工作，重點強調在整個旅行疫苗接種生態系統中保持准入、增強韌性和協調相關人員行為的策略重點。

維持可靠且便利的旅客免疫接種服務需要臨床、商業和政策部門的協調努力。科學創新、數位轉型和不斷變化的貿易政策相互作用，為疫苗供應和交付的相關人員帶來了機會和挑戰。有效應對這一環境需要前瞻性的供應鏈策略、尊重不同群體差異的有針對性的病人參與，以及反映當地流行病學背景和監管條件的本地化方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：旅行疫苗市場：依疫苗類型分類

  • 甲型肝炎
  • B型肝炎
  • 流感
  • 腦膜炎奈瑟菌
  • 狂犬病
  • 傷寒
  • 黃熱病

第9章：旅行疫苗市場：依形式分類

  • 注射藥物
  • 口服

第10章：旅行疫苗市場：依年齡層別分類

  • 成人版
  • 兒童

第11章：旅行疫苗市場：依最終用戶分類

  • 醫院和診所
  • 網路藥房
  • 藥局
  • 旅行專科診所

第12章 旅行疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：旅行疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 旅行疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國旅行疫苗市場

第16章：中國旅行疫苗市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Bio-Manguinhos
  • Bio-Med（P）Limited
  • Biological E Limited
  • Cadila Pharmaceuticals Limited
  • CSL Limited
  • Dano Vaccines & Biologicals Private Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Incepta Pharmaceuticals Ltd.
  • Indian Immunologicals Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Perusahaan Umum（Persero）Bio Farma
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-0316851957A3

The Travel Vaccines Market was valued at USD 14.13 billion in 2025 and is projected to grow to USD 15.36 billion in 2026, with a CAGR of 9.06%, reaching USD 25.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.13 billion
Estimated Year [2026] USD 15.36 billion
Forecast Year [2032] USD 25.93 billion
CAGR (%) 9.06%

A concise and authoritative framing of why travel immunization remains essential amid rising mobility patterns and shifting traveler expectations

Travel-related immunization remains a critical public health intervention as cross-border mobility resumes and diversifies. Pre-travel vaccination practices protect both individual travelers and broader host communities by limiting transmission of vaccine-preventable diseases associated with tourism, business travel, migration, and humanitarian deployments. Travelers consult an evolving mix of clinical guidelines, destination-specific entry requirements, and digital health credentials when preparing for trips, and these factors shape demand patterns for core vaccines such as hepatitis, influenza, and yellow fever.

Clinicians and public health authorities continue to adapt vaccination protocols to align with emerging epidemiological data and shifting traveler profiles. The growing prevalence of medical tourism and expatriate assignments has amplified the need for streamlined access to specialized vaccines and reliable post-exposure prophylaxis, particularly for diseases such as rabies and typhoid. Meanwhile, consumer behavior has shifted toward convenience and digital-enabled services, with more travelers seeking pre-travel consultations through telemedicine, rapid access to immunization records, and fulfillment via pharmacies and online channels. These dynamics underscore the importance of integrating clinical guidance, supply chain resilience, and patient-facing technologies to deliver dependable and accessible travel vaccination services.

How scientific innovation, digital enablement, and regulatory complexity are converging to reshape global travel vaccination delivery models and stakeholder strategies

The travel vaccine landscape is undergoing transformative shifts driven by advances in vaccine science, digital health integration, and the geopolitical context that shapes supply chains. Technological progress, including novel platforms and improved cold-chain solutions, is enabling more durable and adaptable vaccine formulations, which in turn affects vaccination schedules, storage requirements, and distribution approaches. Concurrently, digital health tools for vaccination record-keeping, pre-travel risk assessment, and appointment scheduling are reshaping patient journeys and expanding access points beyond traditional clinical settings.

Regulatory alignment across jurisdictions is improving but remains uneven, prompting industry stakeholders to adopt more flexible compliance strategies and to invest in cross-border data interoperability. In parallel, heightened public scrutiny around vaccine safety and efficacy has intensified the need for clear, evidence-based communication from clinicians and manufacturers. As a result, organizations are prioritizing trust-building measures, transparent supply-chain practices, and partnerships with local providers to ensure both preparedness and rapid response capability when outbreak risks change. These structural shifts collectively require a more integrated approach that combines scientific innovation, digital enablement, and resilient logistics to meet traveler needs effectively.

Examining the ripple effects of altered import tariff dynamics on procurement, cold-chain logistics, and service delivery across travel immunization networks

Policy changes in trade and tariff regimes can materially influence the logistics and availability of vaccines and associated supplies that support travel immunization programs. When import duties or tariffs increase on vaccine components, packaging materials, or cold-chain equipment, actors across the supply chain adjust procurement and inventory strategies to absorb cost pressures or to preserve margin. Manufacturers and distributors may re-evaluate supplier contracts, accelerate localization efforts, or prioritize stockpiling of critical inputs to mitigate disruption.

These adjustments cascade to service providers who operate travel clinics, hospital immunization programs, and retail pharmacy channels. Clinics with narrow operating margins may revise service pricing, negotiate different supply terms, or shift sourcing toward domestically produced alternatives where feasible. At the same time, freight and logistics partners must adapt routing and warehousing strategies to maintain temperature-sensitive integrity while controlling costs. From a strategic standpoint, sustained tariff changes prompt stakeholders to strengthen vendor diversification, increase transparency in procurement, and engage proactively with policymakers to clarify exemptions and harmonized standards. In effect, trade policy volatility amplifies the need for contingency planning across clinical, commercial, and regulatory frontiers to maintain reliable access to travel vaccines and related services.

Actionable segmentation insights that clarify how vaccine type, delivery form, age groups, and end-user channels must inform differentiated clinical and commercial strategies

A nuanced understanding of segmentation is essential for tailoring clinical guidance, distribution approaches, and commercial strategies across the travel vaccination ecosystem. Vaccine type composition matters because different pathogens and immunization regimens-such as those for hepatitis A and B, influenza, meningococcal disease, rabies, typhoid, and yellow fever-carry distinct clinical urgency, pre-travel timing, and storage considerations; therefore, supply prioritization and clinician workflows must reflect these clinical differences. Form factors influence delivery logistics and patient preference, as injectable formulations dominate in clinical settings due to efficacy and established administration protocols, while oral vaccines offer alternative pathways for certain traveler groups and can ease outreach in low-resource or remote scenarios.

Age group segmentation creates divergent clinical pathways and communication needs; adult travelers commonly require routine boosters or destination-specific immunizations, whereas pediatric travelers demand age-appropriate dosing, consent pathways, and integration with routine childhood vaccination schedules. End-user segmentation affects distribution and access: hospitals and clinics handle complex clinical cases and specialist immunizations, pharmacies offer convenient walk-in access and replenishment, travel clinics provide tailored pre-travel risk assessment and multi-dose schedules, and online pharmacies extend reach through home delivery and digital record synchronization. By aligning product portfolios, service models, and patient engagement tactics to these segmentation dimensions, stakeholders can enhance coverage, reduce missed opportunities for vaccination, and improve the overall traveler experience.

Regional dynamics and practical implications for travel vaccine delivery across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic context shapes disease prevalence, regulatory frameworks, and service delivery models, requiring region-specific approaches to travel vaccination. In the Americas, public health systems and private providers coordinate to address endemic risks such as yellow fever in parts of South America and to support large-scale seasonal influenza campaigns that intersect with travel patterns. This region also demonstrates advanced distribution networks and a growing adoption of digital health credentials, enabling more seamless pre-travel clearance and post-vaccination documentation for travelers moving between subregions.

Europe, the Middle East, and Africa present a diverse regulatory landscape and a wide range of clinical capacities. Several European countries maintain rigorous pre-travel advisory services and centralized vaccination programs, while parts of Africa face persistent challenges related to cold-chain infrastructure and access to specialized vaccines. The Middle East is an important transit corridor with high passenger throughput, which elevates the importance of vaccination verification and outbreak preparedness. Asia-Pacific is characterized by robust manufacturing capability in some markets, rising demand driven by outbound tourism, and persistent endemic concerns such as typhoid and rabies in specific subregions. The region also shows rapid growth in digital health adoption and private-sector innovation, which supports expanded access through pharmacies and telehealth-enabled travel clinics. Understanding these regional differences enables more effective allocation of clinical resources, targeted public health messaging, and strategic partnerships that reflect local needs and capacities.

How leading manufacturers, distributors, and service providers are reshaping portfolios, partnerships, and operational resilience to secure travel vaccination delivery

Industry participants are responding to both clinical imperatives and commercial opportunities by adapting portfolios, extending distribution partnerships, and investing in manufacturing and logistics capabilities. Leading vaccine producers and product innovators are expanding their development pipelines to address travel-related pathogen diversity and to improve formulation stability and administration convenience. At the same time, distributors and service providers are forging closer collaborations with specialty travel clinics and pharmacy networks to streamline appointment scheduling, cold-chain handling, and record-keeping.

Commercial strategies increasingly emphasize resilience and flexibility: companies are exploring capacity-sharing agreements, regional fill-and-finish operations, and tiered pricing mechanisms to address procurement variability. Strategic alliances with digital platform providers enable integrated pre-travel assessments, automated reminders for multi-dose series, and smoother verification of immunization status at points of care. Additionally, quality assurance and regulatory readiness remain central to company planning, with firms investing in robust pharmacovigilance and in-market support to sustain clinician confidence and to navigate complex approval pathways across jurisdictions.

Practical and prioritized strategic actions that industry leaders should implement to reinforce supply resilience, digital access, and targeted stakeholder collaboration

Leaders in the travel vaccine ecosystem should prioritize a set of practical actions that strengthen clinical service delivery and commercial viability. First, invest in supply chain redundancy and cold-chain optimization to reduce vulnerability to trade policy shocks and logistical disruptions; this includes establishing alternative suppliers, regional fill-and-finish capabilities, and transparent inventory management systems. Second, accelerate digital integration across the traveler journey by deploying interoperable vaccination records, telemedicine pre-travel assessments, and automated appointment and dosing reminders to increase uptake and minimize missed opportunities.

Third, tailor engagement models to segmentation and regional needs by aligning product offerings and distribution channels with vaccine type, form, age group, and end-user characteristics. Fourth, enhance stakeholder collaboration by building strategic partnerships among manufacturers, distributors, travel clinics, and pharmacy networks to enable coordinated response to outbreak risks and to streamline patient access. Fifth, strengthen public communication strategies to address hesitancy through evidence-based messaging, clinician training, and targeted outreach for high-risk traveler cohorts. Finally, embed regulatory and policy engagement in planning to influence tariff and trade discussions, secure exemptions where possible, and support harmonized standards that facilitate cross-border vaccine movement and recognition.

A rigorous mixed-methods research approach combining primary interviews, policy review, and supply-chain analysis to underpin practical travel vaccination insights

The research underpinning these insights employed a mixed-methods approach designed to capture clinical, operational, and policy dimensions of travel immunization. Primary qualitative interviews were conducted with clinicians, travel-medicine specialists, supply-chain managers, and regulatory experts to gather direct observations about service delivery challenges and adaptation strategies. Secondary source synthesis drew on peer-reviewed literature, public health agency guidance, trade policy documents, and logistics reports to validate clinical pathways, storage requirements, and the regulatory context affecting cross-border vaccine movement.

Analytical methods combined thematic analysis of interview transcripts with supply-chain mapping and comparative policy review across the principal regions. Triangulation procedures ensured that reported findings aligned with multiple independent information sources and that conclusions reflected convergent evidence rather than single-source assumptions. The methodology also accounted for limitations: while qualitative depth provided rich operational detail, stakeholder perspectives may vary by market and subpopulation, and rapid policy changes can alter regulatory conditions. To address this, the research incorporated continuous validation checkpoints with clinical advisors and logistics partners to ensure practical relevance and timeliness of insights.

Conclusive synthesis emphasizing strategic priorities for preserving access, building resilience, and aligning stakeholder actions across the travel vaccination ecosystem

Maintaining reliable and accessible travel immunization services requires coordinated action across clinical, commercial, and policy domains. The converging forces of scientific innovation, digital transformation, and evolving trade policy create both opportunities and vulnerabilities for stakeholders who manage vaccine supply and delivery. Effectively navigating this environment demands proactive supply-chain strategies, targeted patient engagement that respects segmentation differences, and regionally tailored approaches that reflect local epidemiology and regulatory conditions.

Organizations that invest in interoperability of vaccination records, strengthen partnerships across distribution channels, and engage constructively with policymakers will be better positioned to sustain access and to respond efficiently when risks change. Importantly, clear communication and clinician-led education remain foundational for maintaining public trust and for ensuring that travelers receive timely, evidence-based protection. By aligning operational tactics with strategic foresight, stakeholders can preserve continuity of care for travelers while advancing resilient and equitable vaccination services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Travel Vaccines Market, by Vaccine Type

  • 8.1. Hepatitis A
  • 8.2. Hepatitis B
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Rabies
  • 8.6. Typhoid
  • 8.7. Yellow Fever

9. Travel Vaccines Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Travel Vaccines Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Travel Vaccines Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacies
  • 11.3. Pharmacies
  • 11.4. Travel Clinics

12. Travel Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Travel Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Travel Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Travel Vaccines Market

16. China Travel Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AstraZeneca PLC
  • 17.7. Bavarian Nordic A/S
  • 17.8. Bharat Biotech International Limited
  • 17.9. Bio-Manguinhos
  • 17.10. Bio-Med (P) Limited
  • 17.11. Biological E Limited
  • 17.12. Cadila Pharmaceuticals Limited
  • 17.13. CSL Limited
  • 17.14. Dano Vaccines & Biologicals Private Limited
  • 17.15. Dynavax Technologies Corporation
  • 17.16. Emergent BioSolutions Inc.
  • 17.17. GlaxoSmithKline plc
  • 17.18. Incepta Pharmaceuticals Ltd.
  • 17.19. Indian Immunologicals Ltd.
  • 17.20. Johnson & Johnson Services, Inc
  • 17.21. Merck & Co., Inc.
  • 17.22. Novartis AG
  • 17.23. Perusahaan Umum (Persero) Bio Farma
  • 17.24. Pfizer Inc.
  • 17.25. Sanofi S.A.
  • 17.26. Serum Institute of India Pvt. Ltd.
  • 17.27. Shenzhen Kangtai Biological Products Co., Ltd.
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Valneva SE
  • 17.30. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)